Clinical study of TACE combined with apatinib for advanced hilar cholangiocarcinoma
10.3760/cma.j.cn113884-20250124-00030
- VernacularTitle:TACE联合阿帕替尼治疗晚期肝门部胆管癌的临床研究
- Author:
Daqian HAN
1
;
Hao LI
1
;
Chao LIANG
1
;
Manzhou WANG
1
;
Yangyang NIU
1
;
Shuguang JU
1
;
Jiacheng WANG
1
;
Jianzhuang REN
1
;
Xinwei HAN
1
;
Xuhua DUAN
1
Author Information
1. 郑州大学第一附属医院放射介入科，郑州 450000
- Publication Type:Journal Article
- Keywords:
Klatskin tumor;
Transcatheter arterial chemoembolization;
Apatinib;
Healing effect;
Safety
- From:
Chinese Journal of Hepatobiliary Surgery
2025;31(4):262-267
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To study the safety and feasibility of transcatheter arterial chemoembolization (TACE) combined with apatinib in the treatment of advanced hilar cholangiocarcinoma.Methods:Clinical data of 41 patients with hilar cholangiocarcinoma admitted to the First Affiliated Hospital of Zhengzhou University from November 2019 to October 2020 were prospectively collected, including 21 males and 20 females, aged (65.1±12.5) years. The drugs used for TACE were albumin paclitaxel and gemcitabine, which were performed once every four to six weeks for no more than six times. Apatinib were adminstered two days after each TACE. The primary endpoint was objective response rate (ORR) and the secondary endpoints were progression-free survival (PFS), overall survival (OS) and adverse events. Patients were followed-up by outpatient, inpatient or telephone review. Survival analysis was performed using the Kaplan-Meier method.Results:Hilar cholangiocarcinoma were confirmed in all 41 patients by pathology. All patients were treated with TACE for at least twice. Twenty-three patients achieved complete remission, 14 stable disease, and four partial remission, with an ORR of 56.1% and a disease control rate of 90.2%. The follow-up duration was (13.3±5.4) months without lost to follow-up. The median PFS was 9.0 months, the median OS was 14.0 months, the 1-year cumulative recurrence-free survival rate was 31.7%, and the 1-year cumulative survival rate was 65.9%. Treatment-related adverse events in this study were predominantly Clavien-Dindo grade 1 or 2, without grade 4 to 5.Conclusion:TACE combined with apatinib treatment could be safe and feasible for advanced hilar cholangiocarcinoma.
